Bovine Casein Hydrolysate (C12 Peptide) Reduces Blood Pressure in Prehypertensive Subjects

• Published in: American journal of hypertension Vol. 20; no. 1; pp. 1 - 5
• Main Authors: Cadée, Jenny A., Chang, Chou-Yue, Chen, Chien-Wei, Huang, Chien-Ning, Chen, Su-Lin, Wang, Chin-Kun
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 2007; Oxford University Press; Elsevier Science
• Subjects: ACE inhibitor; Aldosterone - blood; Angiotensin II - blood; Angiotensin-Converting Enzyme Inhibitors - adverse effects; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Animals; Arterial hypertension. Arterial hypotension; Biological and medical sciences; Blood and lymphatic vessels; Blood Pressure - drug effects; C12 Peptide; Cardiology. Vascular system; casein hydrolysate; Caseins - adverse effects; Caseins - therapeutic use; Cattle; Clinical manifestations. Epidemiology. Investigative techniques. Etiology; Double-Blind Method; Female; Fundamental and applied biological sciences. Psychology; Hemodynamics. Rheology; Humans; Hypertension; Hypertension - prevention & control; Male; Medical sciences; Middle Aged; Vertebrates: cardiovascular system; Hypertension; C12 Peptide; ACE inhibitor; casein hydrolysate; Human; Bovine; Cardiovascular disease; Vertebrata; Mammalia; Animal; Arterial pressure; Blood pressure; Artiodactyla; Ungulata
• ISSN: 0895-7061; 1879-1905; 1941-7225
• DOI: 10.1016/j.amjhyper.2006.06.005

About one in four adults suffer from prehypertension. People with prehypertension are at risk of developing hypertension, being a biomarker for cardiovascular disease risk. The use of milk-derived protein hydrolysates containing peptides with angiotensin-converting enzyme (ACE) inhibiting properties may reduce blood pressure (BP) and thus the risk of developing hypertension. We investigated the BP-lowering effect of a casein-derived protein hydrolysate (C12 Peptide) during a 4-week intervention period in prehypertensive subjects. After a 2-week run-in period, 48 Taiwanese volunteers were randomly assigned to either placebo or C12 Peptide tablets for 4 weeks, followed by a 2-week off-treatment period. After the run-in period, BP was measured weekly. Baseline values for systolic BP (mean ± SEM) in the placebo and C12 Peptide groups were 137.1 ± 3.1 and 137.9 ± 2.4 mm Hg, respectively; those for diastolic BP were 85.2 ± 2.1 and 86.9 ± 2.0 mm Hg, respectively. Four weeks repeated daily intake of 3.8 g C12 Peptide reduced significantly systolic and diastolic BP by 10.7 ± 1.6 mm Hg and 6.9 ± 1.2 mm Hg, respectively, compared to baseline. Furthermore, plasma angiotensin II and aldosterone levels were reduced significantly ( P < .05). The placebo group showed a BP reduction of 3.6 ± 2.4 and 2.7 ± 1.6 mm Hg in systolic and diastolic BP, respectively ( P = not significant). No evidence of side effects was observed. This study shows that C12 Peptide reduces BP in prehypertensive people.